Overall rank by patents
#4,118
of 49,997 tracked assignees
USPTO PatentsView assignee record - 87 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Glaxosmithkline ranks #4,118 of 49,997 tracked US assignees by granted-patent volume, with 87 patents across 16 technology areas.
USPTO PatentsView assignee plate
Corpus R4118 · Foreign Corporation #4,118 · 87 grants
GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL
Nearest grant-volume peer: Daramic, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Innovex Downhole… · near
42 score
Sangamo Therapeutics · near
42 score
GlaxoSmithKline… · this assignee
42 score
Mainstay Medical · near
42 score
Response · near
42 score
3D Lighting… · lowest
7 score
What this shows Glaxosmithkline's Innovation Score is 41.7/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
GlaxoSmithKline Intellectual Property (No. 4) Limited is a focused PatentsView assignee: 16 CPC subclasses with 95.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (13 grants) versus a trough of 1 in 2023. By volume, Glaxosmithkline sits between Daramic, LLC and Luxshare Precision Industry Company Limited.
From 2019–2021 to 2022–2024, GlaxoSmithKline Intellectual Property (No. 4) Limited moved from 32 to 13 grants (0.41x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Daramic, LLC
87 patents
Dummen Group B.V.
87 patents
F-Secure Corporation
87 patents
Fujikoki Corporation
87 patents
Hunter's Manufacturing Company, Inc.
87 patents
Ishihara Sangyo Kaisha, Ltd.
87 patents
Kwang Yang Motor Co., Ltd.
87 patents
Luxshare Precision Industry Company Limited
87 patents
GlaxoSmithKline Intellectual Property (No. 4) Limited
87 patents
What this shows GlaxoSmithKline holds 87 patents at rank #4,118, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #4,118 in granted patent volume.
Other assignees with the most granted patents in GlaxoSmithKline's primary technology class.
Two PlainPatent-derived peer sets for GlaxoSmithKline, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (42 here).
Nearest assignees by average claims per patent (15.7 here).
Glaxosmithkline's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
42 Top 32% higher than 68% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 8 | 9.2% |
| 2016 | 7 | 8.0% |
| 2017 | 13 | 14.9% |
| 2018 | 7 | 8.0% |
| 2019 | 11 | 12.6% |
| 2020 | 13 | 14.9% |
| 2021 | 8 | 9.2% |
| 2022 | 11 | 12.6% |
| 2023 | 1 | 1.1% |
| 2024 | 1 | 1.1% |
| 2025partial year | 7 | 8.0% |
Top 15 of 16 technology areas
Overall rank by patents
#4,118
of 49,997 tracked assignees
41.7 out of 100
What to do with this data
GlaxoSmithKline Intellectual Property (No. 4) Limited's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.